USE OF TERIPARATIDE IN SURGICAL PLANNING FOR PATIENTS WITH OSTEOPOROSIS

Q4 Medicine Coluna/ Columna Pub Date : 2023-01-01 DOI:10.1590/s1808-185120222203270489
RICARDO CEPEDA JORDAN, PEDRO LUIS BAZáN, JOSé CARLOS SORIA ADARO
{"title":"USE OF TERIPARATIDE IN SURGICAL PLANNING FOR PATIENTS WITH OSTEOPOROSIS","authors":"RICARDO CEPEDA JORDAN, PEDRO LUIS BAZáN, JOSé CARLOS SORIA ADARO","doi":"10.1590/s1808-185120222203270489","DOIUrl":null,"url":null,"abstract":"ABSTRACT Currently, there are no guidelines for treating osteoporosis in spinal surgery. The rate of complications such as screw loosening, proximal junction kyphosis, cage subsidence, and loss of reduction in fractures is high. Objective: To evaluate the use of teriparatide and denosumab in planning spinal surgery in an osteoporotic patient with degenerative pathology, emphasizing the fusion rate, bone mineral density, and decreased complications. Method: A systematic search was performed in medical reference databases for comparative studies of teriparatide and denosumab in spinal surgery to evaluate fusion, screw loosening, bone mineral density, and decrease in the incidence of vertebral fractures. χ2 was implemented for the statistical analysis, according to PRISMA (2020). Result: Fusion rate with teriparatide was 79.28% in the first six months, 95% CI (OR 2.62) and decreased screw loosening rate 81.9% 95% CI (OR 0.6). Increase in bone mineral density 15.5% OR 1.49 (0.77 - 2.86) and decrease in vertebral fracture rate 85.4% OR 0.5. Conclusions: Teriparatide and denosumab should be considered in perioperative spinal planning due to their effectiveness, synergism, and low adverse effects; to improve bone mineral density and decrease the rate of complications. Clinical, comparative, and statistically significant studies are required to confirm this. Level of Evidence II; Systematic Review and Meta-analysis.","PeriodicalId":40025,"journal":{"name":"Coluna/ Columna","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coluna/ Columna","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/s1808-185120222203270489","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

ABSTRACT Currently, there are no guidelines for treating osteoporosis in spinal surgery. The rate of complications such as screw loosening, proximal junction kyphosis, cage subsidence, and loss of reduction in fractures is high. Objective: To evaluate the use of teriparatide and denosumab in planning spinal surgery in an osteoporotic patient with degenerative pathology, emphasizing the fusion rate, bone mineral density, and decreased complications. Method: A systematic search was performed in medical reference databases for comparative studies of teriparatide and denosumab in spinal surgery to evaluate fusion, screw loosening, bone mineral density, and decrease in the incidence of vertebral fractures. χ2 was implemented for the statistical analysis, according to PRISMA (2020). Result: Fusion rate with teriparatide was 79.28% in the first six months, 95% CI (OR 2.62) and decreased screw loosening rate 81.9% 95% CI (OR 0.6). Increase in bone mineral density 15.5% OR 1.49 (0.77 - 2.86) and decrease in vertebral fracture rate 85.4% OR 0.5. Conclusions: Teriparatide and denosumab should be considered in perioperative spinal planning due to their effectiveness, synergism, and low adverse effects; to improve bone mineral density and decrease the rate of complications. Clinical, comparative, and statistically significant studies are required to confirm this. Level of Evidence II; Systematic Review and Meta-analysis.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
特立帕肽在骨质疏松患者手术计划中的应用
目前,脊柱手术中治疗骨质疏松尚无指南。并发症的发生率很高,如螺钉松动、近端关节后凸、固定架下沉和骨折复位丧失。目的:评价特立帕肽和地诺单抗在骨质疏松伴退行性病理患者脊柱手术计划中的应用,强调融合率、骨密度和并发症的减少。方法:系统检索医学参考数据库,比较特立帕肽和地诺单抗在脊柱外科手术中的应用,评价融合、螺钉松动、骨密度和椎体骨折发生率的降低。χ2进行统计分析,参照PRISMA(2020)。结果:前6个月特立帕肽的融合率为79.28%,95% CI (OR 2.62),螺钉松动率降低81.9%,95% CI (OR 0.6)。骨密度升高15.5%或1.49(0.77 - 2.86),椎体骨折率降低85.4%或0.5。结论:特立帕肽和地诺单抗因其有效性、协同性和低不良反应,在围手术期脊柱规划中应考虑;提高骨密度,降低并发症发生率。需要临床、比较和统计上有意义的研究来证实这一点。证据水平II;系统评价和荟萃分析。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Coluna/ Columna
Coluna/ Columna Medicine-Surgery
CiteScore
0.40
自引率
0.00%
发文量
32
审稿时长
10 weeks
期刊最新文献
ADOLESCENT IDIOPATHIC SCOLIOSIS: PROGRESSION OF UNTREATED CASES FUNCTIONALITY OF INDIVIDUALS WITH LOW BACK PAIN: CROSS-SECTIONAL STUDY WITH ICF CORE SET ANESTHETIC BLOCK OF THE INTERTRANSVERSE SEPTUM, A PROSPECTIVE OBSERVATIONAL STUDY LUMBAR LORDOSIS VARIATION ACCORDING THE TYPE OF POSITIONER USED IN LUMBAR ARTHRODESIS CLINICAL PHOTOGRAPHIC AND RADIOLOGICAL CORRELATION IN PATIENTS WITH SCOLIOSIS
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1